[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hospital Center Guillaume Régnier\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":158},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,79,103,129],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100646932","longitudinal-study-on-the-sustainability-of-transcranial-magnetic-stimulation-protocols---biomarkers-100646932",false,"NCT07684911","Longitudinal Study on the Sustainability of Transcranial Magnetic Stimulation Protocols - Biomarkers","LONGISTIM-BIO","Inclusion Criteria:\n\n* Patients aged 18 or older.\n* Patients who have experienced treatment-resistant unipolar or bipolar depression and responded to a previous TMS course (response defined by a 50% reduction in MADRS score).\n* Sufficient command of French to complete questionnaires and follow instructions during MRI assessments and TMS treatments.\n* Willingness to comply with all study procedures, including availability for the duration of the study, and to communicate with study staff about adverse events and other clinically relevant information.\n* Patients who have expressed their informed written consent to participate in the study.\n* Person affiliated with a social welfare scheme or other scheme.\n\nNon-inclusion Criteria:\n\n* Current psychiatric comorbidity (suicidal risk, psychotic episode).\n* Unstable somatic pathology: active cancer, unstabilized endocrinological pathology, untreated sleep apnea.\n* For neuroimaging: Contraindications to magnetic resonance imaging (MRI) such as ferromagnetic metal in the body or severe claustrophobia\n* Adults under legal protection (legal guardianship, conservatorship, trusteeship), persons deprived of their liberty\n* Pregnancy or breast-feeding.","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","OBSERVATIONAL","Despite advances in the effective treatment of major depressive disorder using repetitive transcranial magnetic stimulation (rTMS), the processes that determine a patient's response trajectory remain poorly understood.\n\nCurrently, there are no validated clinical or neurophysiological markers that can identify factors predicting the durability of the response to rTMS at the individual level. This constitutes a major limitation for planning individualised treatments and highlights the need for precision medicine approaches and reliable biomarkers to predict the long-term efficacy of TMS-based interventions, thereby enabling more informed clinical decisions and optimised resource allocation.\n\nrTMS is assumed to work by inducing neuroplasticity on multiple levels of the nervous system, ranging from modulating neurotransmitter release to changing structural and functional brain circuits. While rTMS likely acts as a universal modulator of neuroplasticity, the exact mechanisms are not fully established, especially regarding long-term durability.\n\nThe LONGISTIM-BIO study (\"Longitudinal Study on the Durability of Transcranial Magnetic Stimulation Protocols - Biomarkers\") aims to explore the duration of the treatment effect following an initial response to a course of TMS treatment and examines potential neurophysiological and clinical\u002Fsociodemographic predictors associated with the trajectories of the treatment effect. More explicitly, it examines neuroplasticity as a biomarker of treatment response durability, and explores its association with heart-brain-coupling (HBC), a physiological marker of rTMS target engagement, as well as inflammation, as measured by a blood test (white blood cells, C-reactive protein (CRP)).\n\nDuring this study, participants undergo an rTMS treatment as per standard clinical care. They receive daily sessions of 20Hz rTMS targeting the left dorsolateral prefrontal cortex during which the heart rate will be recorded. Before the first rTMS session, after the last session, and one month after the last session, the severity of depression is evaluated using both the MADRS and the PHQ-8 questionnaire. At the one-month follow-up, the effectiveness of the course is determined by a 50% improvement in the MADRS score. Following the 1-month follow-up visit, if meeting the inclusion criteria, patients will receive bi-weekly assessments of depression severity (PHQ-8 as primary and MADRS self-rated questionnaire as secondary outcome). If two consecutive PHQ-8 questionnaires are pathological (score ≥10), a new rTMS course is scheduled with the shortest delay possible.\n\nDuring this new course of treatment, participation in the study includes:\n\n* a blood draw prior to the first TMS session\n* 4 magnetic resonance imaging (MRI) scans: #1 before the course of treatment, #2 at the end of the course, #3 one month after the end of the treatment, and #4 upon the expected date of relapse.\n\nPatients will again be monitored using self-report questionnaires (PHQ-8 and MADRS-SR) every 2 weeks until a relapse occurs.",[24,25,26],"Depression - Major Depressive Disorder","Depression Bipolar","Depression Unipolar",[28,25,29,30,26,31,32,33,34],"Major Depressive Disorder","Repetitive Transcranial Magnetic Stimulation","rTMS","Durability","Neuroplasticity","Inflammation","heart rate","RECRUITING","2026-06-29",{"date":38,"type":39},"2026-07-06","ACTUAL",{"date":41,"type":39},"2026-06-04",{"date":43,"type":20},"2029-08",{"name":45,"class":46},"Hospital Center Guillaume Régnier","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":68,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},"100645267","belief-update-the-effects-of-depression-and-antidepressants-in-older-people-100645267","NCT07681492","Belief Update: The Effects of Depression and Antidepressants in Older People","OLDBELIEFS","Inclusion Criteria for patients with major depressive disorder :\n\n* Patient over 65 years old in outpatient care\n* Patients with major depressive disorder or patients with bipolar major depressive disorder as evaluated by the Mini International Neuropsychiatric Interview (MINI) semi-structured interview for the group suffering from depression\n* Absence of cognitive impairment as evidenced by an MMSE (Mini Mental State Examination) ≥ 24\n* MADRS ≥ 20\n* MMSE ≥ 24\n* Change of antidepressants\n* Person affiliated with a social security scheme\n* Patients who have received informed information about the study and have signed a consent form to participate in the study\n\nExclusion Criteria with major depressive disorder :\n\n* mental disorders other than mood disorders : attention deficit dissorder, borderline personality disorder, schizophrenia, autism spectrum disorder, anorexia-bulimia disorder, obsessive-compulsive disorder, anxiety disorders and substance use disorder (except tobacco).\n* Inability to understand task instructions and perform the behavioral task\n* Neurological or neurosurgical comorbidities\n* Major visual impairment\n* Adults under state medical aid\n* Adults under legal protection (legal guardianship, curatorship, trusteeship), persons deprived of their liberty\n\nInclusion Criteria for patients with major depressive disorder :\n\n* Absence of psychiatric disorders attested by administration of the MINI\n* Absence of cognitive impairment as evidenced by an MMSE ≥ 24",true,"65 Years",{"count":58,"type":20},62,"INTERVENTIONAL",[61],"NA","People in good health do not perceive the future in the same way as those suffering from depression. This difference in perception affects behaviour and emotions and warrants further investigation, both before and after treatment with antidepressants. Research shows that past negative experiences with medication can reduce the effectiveness of treatment, whilst positive expectations can increase it. It is important to gain a better understanding of how antidepressants influence the way in which elderly people with major depressive disorder (MDD) change their beliefs, and to determine whether an improvement in their depressive symptoms is linked to these changes in their beliefs. This study aims to understand whether antidepressants can alter the way people view the future and whether this contributes to their effectiveness. It also seeks to determine whether patients' expectations regarding treatment influence clinical outcomes, and whether changes in their mood may in turn affect these expectations. The study will involve 31 patients aged 65 and over who are suffering from a depressive disorder and require a change of antidepressant, and 31 healthy subjects, also aged 65 and over. The participants' involvement will last for 12 weeks.\n\nDuring a medical consultation, once the doctor has checked that the participant meet all the study's eligibility criteria, they will ask for the participant consent to take part in the study. The participant will then be asked to answer one question about what you hope to gain from the new antidepressant treatment that the doctor will prescribe for the participant. Finally, the participant will carry out a belief-updating exercise, which involves : presenting the participant with a series of events and ask them to indicate how likely they think each of them is to occur, and then. Once they have received further information about these events, ask them to reassess the likelihood of them occurring. This task will be carried out again 12 weeks after the participant start taking their antidepressant, during a consultation required as part of their individual care plan. From the first week of antidepressant treatment until week 12, the participant will be contacted by telephone once a week to answer two short questions about their expectations regarding the treatment and any changes in your mood.",[64,65,66,67],"Major Depressive Episode (MDE)","Beliefs","Beliefs About Future","Depression",[64,65,69,67],"Beliefs about future","2026-06-26",{"date":72,"type":39},"2026-07-02",{"date":74,"type":39},"2025-01-14",{"date":76,"type":20},"2027-10",{"name":45,"class":46},2,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":47},"100633493","impact-of-theta-burst-repetitive-transcranial-magnetic-stimulation-on-the-patients-self-reported-improvement-in-their-motor-functional-neurological-disorder-100633493","NCT07527403","Impact of Theta Burst Repetitive Transcranial Magnetic Stimulation on the Patient's Self-reported Improvement in Their Motor Functional Neurological Disorder","Thêta-mTNF","Inclusion Criteria:\n\n* Patients over 18\n* Patients with FND, either deficits or abnormal movements, diagnosed by a neurologist.\n* Patients with an indication for validated neuronavigated rTMS treatment.\n* Patients who have indicated that they do not object to participating in the study.\n\nExclusion Criteria:\n\n* Patients subject to legal protection (legal guardianship, conservatorship, trusteeship)\n* Patients deprived of liberty",{"count":87,"type":20},22,"Functional neurological disorder (FND) is a condition that causes significant suffering and disability. It is defined by the presence of neurological symptoms that interfere with an individual's functioning and are not consistent with any known anatomical lesion but that causes significant functional impairment. The investigators are particularly interested in motor symptoms (abnormal movements or motor deficits).\n\nRepetitive transcranial magnetic stimulation (rTMS) is a non-invasive and acceptable treatment that has proven effective in certain chronic pain conditions, depression, and OCD. The investigators would like to evaluate the impact of rTMS on the patient's overall perception of change, particularly on the clinical symptoms of motor FND. Secondary objectives include evaluating the overall effect on symptoms from the clinician's perspective, the effect on quality of life, on depressive and anxiety symptoms and associated dissociation, as well as evaluating any changes in the sense of agency and identifying the side effects of rTMS treatment.",[90,91],"Functional Neurological Disorder","Motor FND",[90,91,93,94],"Repetitive Transcranial Magnectic Stimulation (rTMS)","Theta burst rTMS","2026-04-15",{"date":97,"type":39},"2026-04-20",{"date":99,"type":39},"2026-03-13",{"date":101,"type":20},"2028-03",{"name":45,"class":46},{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":56,"enrollmentInfo":111,"targetDuration":4,"studyType":59,"phases":113,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":47},"100612848","feasibility-and-efficacy-of-rtms-in-depression-in-patients-with-autism-spectrum-disorder-asd-100612848","NCT07258914","Feasibility and Efficacy of rTMS in Depression in Patients With Autism Spectrum Disorder (ASD)","Feasibility and Efficacy of rTMS in Depression in Individuals With Autism Spectrum Disorder (ASD)","DEPASS'R","Inclusion Criteria:\n\n* Patient with a diagnosis of ASD validated by a psychiatrist or line 2\n* Patient aged 18 to 65...\n* Patients suffering from EDM (MADRS greater than 20)\n* No change in treatment in the month prior to inclusion\n* Patients affiliated with or entitled to social security\n* Patients who have received informed information about the study and have signed a consent form to participate in the study\n\nExclusion Criteria:\n\n* Patients with psychiatric comorbidity (decompensated manic state, schizophrenic disorder)\n* Pregnancy at the time of inclusion\n* Patients with contraindications to rTMS and MRI (history of epilepsy, neurological stimulator, pacemaker, cardiac defibrillator, cardiac prosthesis, vascular prosthesis, intracranial clips or clamps, cerebrospinal fluid shunt, metal fragments in the eyes, claustrophobia)\n* Adults under legal protection (legal guardianship, curatorship, trusteeship), persons deprived of their liberty, persons hospitalised under compulsion (SDT, SDRE).",{"count":112,"type":20},25,[61],"Depression is a common complication of Autism Spectrum Disorder (ASD): it is four times more prevalent in people with ASD than in the general population.\n\nHowever, treating depression in people with ASD is complicated by the lack of guidelines. Antidepressants appear to be less effective and less well tolerated than in the general population.\n\nrTMS (repetitive transcranial magnetic stimulation) is a technique that stimulates the brain in a painless and non-invasive way. This technique is well tolerated and has very few side effects (headaches, fatigue). It is now used routinely in clinical practice to treat resistant depression, with satisfactory results.\n\nA few studies using rTMS in depression in people with ASD have shown encouraging results and avenues for improvement.\n\nIt could therefore be interesting to conduct a therapeutic study with rTMS on depression in people with ASD, following the avenues for improvement proposed by previous studies.\n\nThe main objective is to evaluate the effectiveness of rTMS in depressed patients with ASD by looking at changes in mood before and after treatment. The investigator will also look at the effects on executive and attentional functions and repetitive behaviors, as well as treatment tolerance.",[116,67,64],"Autism Spectrum Disorder",[116,67,64,118,93,30,119,120],"Transcranial Magnetic Stimulation","Neurodivergent","executive and attentional function","2025-11-21",{"date":123,"type":39},"2025-12-02",{"date":125,"type":39},"2024-12-19",{"date":127,"type":20},"2026-02-19",{"name":45,"class":46},{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":55,"sex":16,"minAge":136,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":139,"conditions":140,"keywords":143,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":47},"100586354","apathy-related-neurobehavioral-markers-of-cognitive-decline-in-old-age-bipolar-disorders-proof-of-concept-100586354","NCT06914284","Apathy-related Neurobehavioral Markers of Cognitive Decline in Old-age Bipolar Disorders: Proof-of-concept","ANACONDA","Inclusion Criteria:\n\n1. Population: Age between 70 and 85 years-old, living at home (Participants living in nursing homes are not included).\n2. Condition: OABD type 1, type 2 and type 3 assessed by the DSM5 criteria\n3. Stable: no MDE or hypomanic state within the last 6 months\n4. Ambulatory setting only\n5. General condition: Successful Gait speed test from the Short Physical Performance Battery (SPPB): beingable to walk 4 meters in 4 seconds (SPPB NIH Toolbox)44\n6. Person affiliated to a social security regime\n7. Patients who have given their free, informed and written consent to take part in the study\n\nExclusion Criteria:\n\n1. Psychiatric conditions and or co-morbidities\n\n   1. Unipolar depression\n   2. Recurrent unipolar depression\n   3. Substance use disorder according to DSM5 criteria. Benzodiaepine and\u002For z-drugs dependence are accepted.\n2. Neurological and cerebral co-morbidities\n\n   1. Major Cognitive Disorder: significant cognitive decline characterized by extensive cognitive tests or at least a standardized clinical evaluation AND at least loss of autonomy in complex instrumental daily living function, not related to delirium (DSM5 criteria)\n   2. Medical history of known degenerative disorders: Alzheimer's disease, Lobar Degenerative Fronto-temporal disorders, Lewy Body disease, corticobasal degenerative disorder, Supranuclear Palsy, epilepsy.\n   3. Medical history of known Parkinson's disease (according to the Movement Disorder Society (MDS)45 criteria)\n   4. Medical history of known stroke\n   5. Severe Parkinsonism (defined by MDS-Unified Parkinson's Disease Rating Scale46 \\> 20)\n3. MRI contra-indications: metallic implants, severe claustrophobia\n4. Adults under legal protection (safeguard of justice, curatorship, guardianship), persons deprived of their liberty.\n5. Hospitalized at inclusion","70 Years","85 Years",{"count":19,"type":20},"The goal of this clinical trial is to identify reliable markers of apathy in elderly subjects with bipolar disorder, age between 70 and 85 years, in order to accurately identify subjects at high risk of progressing to dementia by measuring motor activity (actimetrics), recorded language and analysing brain changes (MRI).\n\nActimetry is the measurement and recording of body movements using an actimeter. This device is worn on the wrist and contains sensors capable of measuring and recording all movements, including those of very low intensity. An automated speech analysis using artificial intelligence is used to detect low-intensity anomalies, and we want to test whether individual differences correspond to individual differences in brain anatomy and function.\n\nResearchers will compare elderly subjects with bipolar disorder and healthy volunteer, age between 70 and 85 years.\n\nParticipants will be asked to:\n\n* Perform an MRI\n* Complete 3 cognitive tests: verbal memory, verbal fluency and an emotional storytelling task, in which you will be asked to describe a memory orally using positive, negative and neutral emotions.\n* wear an actimeter on your wrist for 4 days.",[141,142],"Apathy","Bipolar Disorder",[141,144,145,146,147,148,149],"Actimetry","Neurobehavioral marker","Cognitive decline","Old Age Bipolar Disorder","MRI","Speech marker","2025-04-03",{"date":152,"type":39},"2025-04-06",{"date":154,"type":39},"2024-07-01",{"date":156,"type":20},"2029-01",{"name":45,"class":46},""]